vs

Side-by-side financial comparison of AvePoint, Inc. (AVPT) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

AvePoint, Inc. is the larger business by last-quarter revenue ($114.7M vs $75.5M, roughly 1.5× PUMA BIOTECHNOLOGY, INC.). On growth, AvePoint, Inc. posted the faster year-over-year revenue change (28.6% vs 27.7%). AvePoint, Inc. produced more free cash flow last quarter ($29.0M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 24.0%).

AvePoint is a public company headquartered in Jersey City, New Jersey, United States. It develops software products intended to add features or security to other major platforms, like Microsoft 365, Google, or Salesforce. AvePoint was founded in 2001 and went public on NASDAQ in 2020.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

AVPT vs PBYI — Head-to-Head

Bigger by revenue
AVPT
AVPT
1.5× larger
AVPT
$114.7M
$75.5M
PBYI
Growing faster (revenue YoY)
AVPT
AVPT
+0.9% gap
AVPT
28.6%
27.7%
PBYI
More free cash flow
AVPT
AVPT
$14.6M more FCF
AVPT
$29.0M
$14.4M
PBYI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
24.0%
AVPT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AVPT
AVPT
PBYI
PBYI
Revenue
$114.7M
$75.5M
Net Profit
$15.6M
Gross Margin
73.6%
69.3%
Operating Margin
12.7%
22.7%
Net Margin
13.6%
Revenue YoY
28.6%
27.7%
Net Profit YoY
191.1%
EPS (diluted)
$0.06
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVPT
AVPT
PBYI
PBYI
Q4 25
$114.7M
$75.5M
Q3 25
$109.7M
$54.5M
Q2 25
$102.0M
$52.4M
Q1 25
$93.1M
$46.0M
Q4 24
$89.2M
$59.1M
Q3 24
$88.8M
$80.5M
Q2 24
$78.0M
$47.1M
Q1 24
$74.5M
$43.8M
Net Profit
AVPT
AVPT
PBYI
PBYI
Q4 25
$15.6M
Q3 25
$13.0M
$8.8M
Q2 25
$2.9M
$5.9M
Q1 25
$3.6M
$3.0M
Q4 24
$-17.2M
Q3 24
$2.6M
$20.3M
Q2 24
$-12.9M
$-4.5M
Q1 24
$-2.0M
$-4.8M
Gross Margin
AVPT
AVPT
PBYI
PBYI
Q4 25
73.6%
69.3%
Q3 25
74.4%
77.7%
Q2 25
74.0%
76.5%
Q1 25
74.3%
77.1%
Q4 24
75.4%
76.4%
Q3 24
76.1%
63.9%
Q2 24
75.7%
77.4%
Q1 24
72.6%
75.5%
Operating Margin
AVPT
AVPT
PBYI
PBYI
Q4 25
12.7%
22.7%
Q3 25
7.4%
17.6%
Q2 25
7.0%
12.7%
Q1 25
3.5%
8.7%
Q4 24
5.4%
22.6%
Q3 24
8.6%
27.4%
Q2 24
-2.7%
-4.6%
Q1 24
-4.3%
-5.3%
Net Margin
AVPT
AVPT
PBYI
PBYI
Q4 25
13.6%
Q3 25
11.9%
16.2%
Q2 25
2.8%
11.2%
Q1 25
3.8%
6.5%
Q4 24
-19.3%
Q3 24
3.0%
25.2%
Q2 24
-16.6%
-9.6%
Q1 24
-2.6%
-11.0%
EPS (diluted)
AVPT
AVPT
PBYI
PBYI
Q4 25
$0.06
$0.26
Q3 25
$0.06
$0.17
Q2 25
$0.01
$0.12
Q1 25
$0.02
$0.06
Q4 24
$-0.09
$0.40
Q3 24
$0.01
$0.41
Q2 24
$-0.07
$-0.09
Q1 24
$-0.01
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVPT
AVPT
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$481.1M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$478.7M
$130.3M
Total Assets
$789.2M
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVPT
AVPT
PBYI
PBYI
Q4 25
$481.1M
$97.5M
Q3 25
$471.6M
$94.4M
Q2 25
$430.1M
$96.0M
Q1 25
$351.8M
$93.2M
Q4 24
$290.9M
$101.0M
Q3 24
$250.0M
$96.7M
Q2 24
$230.8M
$96.8M
Q1 24
$219.3M
$107.2M
Total Debt
AVPT
AVPT
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
AVPT
AVPT
PBYI
PBYI
Q4 25
$478.7M
$130.3M
Q3 25
$466.8M
$115.3M
Q2 25
$443.1M
$104.7M
Q1 25
$361.5M
$97.1M
Q4 24
$270.9M
$92.1M
Q3 24
$215.7M
$71.1M
Q2 24
$207.4M
$48.5M
Q1 24
$212.7M
$51.0M
Total Assets
AVPT
AVPT
PBYI
PBYI
Q4 25
$789.2M
$216.3M
Q3 25
$743.5M
$202.9M
Q2 25
$700.1M
$194.9M
Q1 25
$598.8M
$196.2M
Q4 24
$519.1M
$213.3M
Q3 24
$463.0M
$220.7M
Q2 24
$427.3M
$205.0M
Q1 24
$413.8M
$214.1M
Debt / Equity
AVPT
AVPT
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVPT
AVPT
PBYI
PBYI
Operating Cash FlowLast quarter
$29.7M
$14.4M
Free Cash FlowOCF − Capex
$29.0M
$14.4M
FCF MarginFCF / Revenue
25.3%
19.1%
Capex IntensityCapex / Revenue
0.6%
0.0%
Cash ConversionOCF / Net Profit
1.90×
TTM Free Cash FlowTrailing 4 quarters
$81.6M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVPT
AVPT
PBYI
PBYI
Q4 25
$29.7M
$14.4M
Q3 25
$34.8M
$9.7M
Q2 25
$20.3M
$14.1M
Q1 25
$495.0K
$3.6M
Q4 24
$32.8M
$15.6M
Q3 24
$32.2M
$11.0M
Q2 24
$16.2M
$1.0M
Q1 24
$7.8M
$11.2M
Free Cash Flow
AVPT
AVPT
PBYI
PBYI
Q4 25
$29.0M
$14.4M
Q3 25
$34.3M
$9.7M
Q2 25
$19.3M
$14.1M
Q1 25
$-1.0M
$3.6M
Q4 24
$32.0M
$15.6M
Q3 24
$30.8M
$11.0M
Q2 24
$15.8M
$1.0M
Q1 24
$7.3M
FCF Margin
AVPT
AVPT
PBYI
PBYI
Q4 25
25.3%
19.1%
Q3 25
31.3%
17.7%
Q2 25
18.9%
26.8%
Q1 25
-1.1%
7.7%
Q4 24
35.9%
26.4%
Q3 24
34.7%
13.7%
Q2 24
20.2%
2.1%
Q1 24
9.7%
Capex Intensity
AVPT
AVPT
PBYI
PBYI
Q4 25
0.6%
0.0%
Q3 25
0.5%
0.0%
Q2 25
0.9%
0.0%
Q1 25
1.6%
0.1%
Q4 24
0.8%
0.0%
Q3 24
1.6%
0.0%
Q2 24
0.5%
0.0%
Q1 24
0.7%
0.0%
Cash Conversion
AVPT
AVPT
PBYI
PBYI
Q4 25
1.90×
Q3 25
2.68×
1.10×
Q2 25
7.01×
2.41×
Q1 25
0.14×
1.21×
Q4 24
Q3 24
12.30×
0.54×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AVPT
AVPT

SAAS$88.9M78%
Services$14.7M13%
Termed License And Support$10.1M9%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons